STADA Arzneimittel AG - 1998 best financial year for the third time in succession. Sales increased in the first quarter of 1999 by 45%. Board of Management expanded from 1 May 1999.

Bad Vilbel, 04/28/1999. STADA Arzneimittel AG announced its figures today for the 1998 financial year.
Sales growth + 25% / Profit growth + 108%
With a 25% increase in sales to DM 503.8 million, 1998 was once again the best ever financial year – for the third time in succession. In terms of EBITDA* STADA Arzneimittel AG recorded growth of 54% to DM 62.9 million. Cash flow increased by 80% to DM 47.4 million. Net income for the year was more than doubled, reaching a level of DM 21.1 million.
The increase in the key financial figures is attributable to a large degree to the acquisition of the company cell pharm GmbH in Hanover and a package of products from the company Fresenius AG in Bad Homburg. STADA has thus moved closer towards its goal of establishing itself as a comprehensive healthcare concern.
Increase in dividend payment
With STADA Arzneimittel AG’s retained earnings of DM 11,782,513.94, the Board of Management and the Supervisory Board will propose to the Annual General Meeting on 29 June 1999 an increase in the dividend for ordinary shares from DM 7.50 to DM 8.50 and for preference shares from DM 8.50 to DM 9.50.
* Earnings before interest, tax, deprecitation and amortisation
45% increase in sales in the first quarter of 1999
In the first quarter of 1999, the company has already registered increased sales of 45%. STADA Arzneimittel AG considers sales of around DM 600 million to be achievable in 1999. This will be supported by increasing investment in sales and marketing and further expansion of the product portfolio. In particular, the recent introduction of Omeprazol in Germany and the planned future introduction of this new STADA generic medicine throughout Europe also promises to deliver further sales growth for STADA.
Improved Internet presence
With its revised Internet site STADA Arzneimittel AG provides an even better overview of the company’s activities and key financial figures.Board of Management expanded
The Board of Management of STADA Arzneimittel AG, which had previously consisted of Hartmut Retzlaff and Dr. Rüdiger Toussaint, is to be strengthened with two additional members. The Supervisory Board of STADA Arzneimittel AG has appointed Dipl.-Kfm. Wolfgang Jeblonski (40) as Finance Director and Dipl.-Ing. Peter Niemann as Technical Director as of 1 May 1999. Both have already been responsible for the corresponding functions at STADA for several years in the capacity of divisional managers.
For more information, please contact:
STADA Arzneimittel AG
Corporate Communications
D-61118 Bad Vilbel
Tel.: +49 6101 603-113
Fax: +49 6101 603-506
e-mail: communications@stada.de

Download in PDF format